Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Boston Scientific Corp (BSX)

NYSE
Currency in USD
90.47
+0.03(+0.03%)
Closed
After Hours
91.45+0.98(+1.08%)
BSX Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
89.6290.79
52 wk Range
53.9391.93
Key Statistics
Edit
Prev. Close
90.43
Open
90
Day's Range
89.62-90.79
52 wk Range
53.93-91.93
Volume
2.88M
Average Volume (3m)
5.89M
1-Year Change
61.08%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
97.00
Upside
+7.22%
Members' Sentiments
Bearish
Bullish
ProTips
20 analysts have revised their earnings upwards for the upcoming period
Show more

Boston Scientific Corp Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corp SWOT Analysis


Impressive Growth
Boston Scientific reports robust 18% organic sales growth, outperforming market expectations and raising 2024 guidance to 15% organic growth
Watchman's Potential
Explore how Watchman FLX device's clinical success could expand addressable market by millions, driving significant growth through the decade
Market Leadership
Delve into Boston Scientific's position as a top-performing large-cap MedTech company, with analysts anticipating meaningful margin expansion
Analyst Outlook
Average price target of $89, ranging from $78 to $98, reflects confidence in BSX's innovative pipeline and market expansion strategies
Read full SWOT analysis
BSX Full Pro Research
Institutional-Grade Stock Analysis
Understand how BSX earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Boston Scientific Corp Earnings Call Summary for Q4/2024

  • Cardiology market expected to grow 8% CAGR through 2027; Boston Scientific reports 27% US and 18% international YTD growth
  • Recent approvals: FARAVIEW mapping software, FARAWAVE NAV catheter; ACURATE platform shows 20% revenue growth in EMEA
  • ACURATE IDE trial missed primary endpoint; company in FDA discussions for US TAVR program and structural heart market
  • Boston Scientific investing in mitral and tricuspid therapies; expects to double global drug-coated balloon business by 2025
  • WATCHMAN FLX Pro device met safety/efficacy endpoints; FARAWAVE and OPAL systems expected to increase market share
Last Updated: 04/11/2024, 02:28
Read Full Transcript

Compare BSX to Peers and Sector

Metrics to compare
BSX
Peers
Sector
Relationship
P/E Ratio
74.4x−6.3x−0.7x
PEG Ratio
1.580.200.00
Price/Book
6.4x4.4x2.6x
Price / LTM Sales
8.4x4.4x3.2x
Upside (Analyst Target)
8.4%13.9%43.2%
Fair Value Upside
Unlock−10.2%6.8%Unlock

Analysts' Recommendations

28 Buy
5 Hold
0 Sell
Ratings:
31 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 97.00

(+7.22% Upside)

People Also Watch

247.51
CEG
-0.83%
813.33
LLY
+1.69%
541.71
ISRG
-0.21%
414.46
ANET
+1.07%
154.15
VST
+0.03%

FAQ

What Is the Boston Scientific (BSX) Premarket Price Today?

The Boston Scientific (BSX) premarket price is . Premarket price change units: . Premarket percentage change: . Premarket volume: . Current date: 03 Dec 2024. Previous close: 90.43

What Stock Exchange Does Boston Scientific Trade On?

Boston Scientific is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Boston Scientific?

The stock symbol for Boston Scientific is "BSX."

What Is the Boston Scientific Market Cap?

As of today, Boston Scientific market cap is 133.44B.

What is Boston Scientific Earnings Per Share?

The Boston Scientific EPS is 1.22.

What Is the Next Boston Scientific Earnings Date?

Boston Scientific will release its next earnings report on 28 Jan 2025.

From a Technical Analysis Perspective, Is BSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Is Boston Scientific (BSX) Price Target According to Analysts?

Based on analysts, the average 12-month price target for Boston Scientific is , with a high estimate of and a low estimate of . analysts recommend buying the stock, while suggest selling, leading to an overall rating of . The stock has an upside potential of %.

What Is Boston Scientific (BSX) Price Target According to Analysts?

Based on analysts, the average 12-month price target for Boston Scientific is , with a high estimate of and a low estimate of . analysts recommend buying the stock, while suggest selling, leading to an overall rating of . The stock has an upside potential of %.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.